Table 2.
Univariate analysis of 28- and 90-day mortality of patients with HBV- ACLF
| Patient’s Characteristics | Univariate analysis (28-day mortality) | Univariate analysis (90-day mortality) | ||||
|---|---|---|---|---|---|---|
| β | OR (95% CI) | p value | β | OR (95% CI) | P value | |
| Age (yr) | 0.037 | 1.037 (1.022–1.053) | < 0.001 | 0.039 | 1.040 (1.026–1.054) | < 0.001 |
| Male % | −0.056 | 0.946 (0.608–1.472) | 0.805 | −0.048 | 0.953 (0.646–1.406) | 0.810 |
| Complications | ||||||
| Hyponatremia (%) | 0.573 | 1.773 (1.259–2.496) | 0.001 | 0.687 | 1.977 (1.465–2.668) | < 0.001 |
| Astices (%) | 0.515 | 1.673 (1.132–2.472) | 0.010 | 0.560 | 1.751 (1.243–2.465) | 0.001 |
| Spontaneous bacterial peritonitis (%) | 0.879 | 2.409 (1.406–4.012) | 0.001 | 0.733 | 2.080 (1.291–3.353) | 0.003 |
| HE | 1.181 | 5.623 (2.358–10.891) | < 0.001 | 1.220 | 2.235 (1.883–4.837) | < 0.001 |
| Hepatorenal syndrome (%) | 1.214 | 3.368 (2.162–5.248) | < 0.001 | 1.277 | 3.585 (2.413–5.326) | < 0.001 |
| Organ failures | ||||||
| Liver (%) | 1.100 | 3.005 (1.726–5.230) | < 0.001 | 1.104 | 3.016 (1.872–4.860) | < 0.001 |
| Kidney (%) | 1.248 | 3.483 (1.921–6.316) | < 0.001 | 1.492 | 4.446 (2.685–7.363) | < 0.001 |
| Brain (%) | 1.987 | 7.295 (4.400–12.094) | < 0.001 | 1.955 | 7.067 (4.394–11.364) | < 0.001 |
| Coagulation (%) | 1.377 | 3.963 (2.808–5.593) | < 0.001 | 1.197 | 3.309 (2.453–4.499) | < 0.001 |
| Circulatory (%) | 3.034 | 20.775 (4.975–86.754) | < 0.001 | 3.034 | 20.775 (4.975–86.754) | < 0.001 |
| Respiratory (%) | 2.457 | 11.673 (1.599–85.199) | 0.015 | 2.457 | 11.673 (1.599–85.199) | 0.015 |
| Treatment with NUCs (%) | −0.547 | 0.388 (0.249–0.604) | < 0.001 | −0.870 | 0.419 (0.281–0.625) | < 0.001 |
| Lamivudine alone (%) | −0.234 | 0.791 (0.527–1.189) | 0.259 | −0.127 | 0.881 (0.624–1.243) | 0.470 |
| Entecavir alone (%) | −0.079 | 0.924 (0.657–1.300) | 0.649 | −0.164 | 0.848 (0.629–1.144) | 0.281 |
| Adefovir alone (%) | −0.159 | 0.853 (0.349–2.085) | 0.727 | −0.439 | 0.644 (0.265–1.569) | 0.333 |
| Telbivudine alone (%) | −3.013 | 0.049 (0.000–208.362) | 0.480 | −0.361 | 0.697 (0.098–4.975) | 0719 |
| ≥ 2 NUCs (%) | −0.329 | 0.719 (0.366–1.416) | 0.340 | −0.079 | 0.924 (0.544–1.569) | 0.770 |
| Laboratory data | ||||||
| ALT (U·L−1) | 0.000 | 1.000 (1.000–1.000) | 0.520 | 0.000 | 1.000 (1.000–1.000) | 0.478 |
| AST (U·L−1) | 0.000 | 1.000 (1.000–1.000) | 0.533 | 0.000 | 1.000 (1.000–1.000) | 0.900 |
| TBIL (μmol·L−1) | 0.003 | 1.003 (1.002–1.004) | < 0.001 | 0.003 | 1.003 (1.003–1.004) | < 0.001 |
| Albumin (g·L−1) | −0.028 | 0.972 (0.938–1.008) | 0.124 | −0.056 | 0.946 (0.917–0.976) | 0.001 |
| GGT (U·L−1) | −0.004 | 0.996 (0.993–0.999) | 0.006 | −0.004 | 0.997 (0.994–0.999) | 0.005 |
| ALP (U·L−1) | −0.005 | 0.995 (0.991–0.999) | 0.009 | −0.003 | 0.997 (0.993–1.000) | 0.034 |
| Cholinesterase (U·L−1) | 0.000 | 1.000 (1.000–1.000) | 0.277 | 0.000 | 1.000 (1.000–1.000) | 0.008 |
| PTA (%) | −0.096 | 0.908 (0.891–0.926) | < 0.001 | − 0.081 | 0.922 (0.907–0.937) | < 0.001 |
| INR | 0.785 | 2.193 (1.936–2.485) | < 0.001 | 0.773 | 2.166 (1.915–2.448) | < 0.001 |
| White blood cell (×109·L−1) | 0.082 | 1.085 (1.050–1.121) | < 0.001 | 0.083 | 1.087 (1.057–1.118) | 0.083 |
| Neutrophil count (×109·L−1) | 0.091 | 1.096 (1.059–1.133) | < 0.001 | 0.092 | 1.097 (1.066–1.129) | < 0.001 |
| Lymphocyte count (× 109·L−1) | − 0.364 | 0.695 (0.521–0.928) | 0.014 | −0.288 | 0.750 (0.587–0.958) | 0.021 |
| NLR | 0.128 | 1.136 (1.078–1.198) | < 0.001 | – | – | – |
| Platelet count (×109·L−1) | −0.002 | 0.998 (0.995–1.002) | 0.371 | 0.148 | 1.159 (1.094–1.229) | < 0.001 |
| Serum potassium (mmol·L−1) | 0.361 | 1.435 (1.140–1.807) | 0.002 | −0.002 | 0.998 (0.995–1.001) | 0.298 |
| Serum sodium (mmol·L−1) | −0.080 | 0.923 (0.892–0.955) | < 0.001 | 0.321 | 1.379 (1.113–1.708) | 0.003 |
| Serum creatinine (mg·dL−1) | 0.005 | 1.005(1.003–1.006) | < 0.001 | −0.096 | 0.909 (0.882–0.937) | < 0.001 |
| HBeAg positive rate | −0.485 | 0.616(0.429–0.884) | 0.009 | 0.005 | 1.005 (1.003–1.006) | < 0.001 |
| HBV-DNA level (Log10copies·mL−1) | 0.031 | 1.032 (0.918–1.160) | 0.602 | −0.485 | 0.616 (0.448–0.847) | 0.003 |
OR odds ratio, 95% CI 95% confidence interval, HBV hepatitis B virus, ACLF acute-on chronic liver failure, NUCs nucleotide analogs, HE hepatic encephalopathy, ALT alanine aminotransferase, AST aspartate aminotransferase, TBIL total bilirubin, GGT gamma-glutamyl transpeptidase, ALP alkaline phosphatase, PTA prothrombin activity, INR international normalized ratio, MELD model of end-stage liver disease, MELD-Na MELD integrating sodium, HBeAg hepatitis B e antigen